Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
White House denies Trump is the well-connected man who gained compassionate access to obesity drug in April A White House spokesman said theories that President Trump sought the drug were baseless speculation Bookmark CommentsGo to comments Multiple White House officials are denying that President Donald Trump was the mystery patient who reportedly got early access to an experimental weight loss drug to treat severe health complications
Emerging concerns: eye conditions (e.g., neovascular age-related macular degeneration), sagging skin, oral health issues, menstrual and bone density changes
doi: 10.3390/nu11071623 71
By Route of Administration: Parenteral dominates, Oral growing fastest Parenteral (subcutaneous injection) delivery held the dominant route of administration position in 2025, reflecting that all high-dose, high-efficacy GLP-1 formulations currently approved for obesity management require injection for the delivery of drug quantities sufficient to achieve therapeutic plasma concentrations
Frequently asked questions What is retatrutide used for
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
